Compare Morgan Stanley (MS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Neurocrine Biosciences Inc — how do they compare? Morgan Stanley trades at $187.86 (market cap $294.39B), while Neurocrine Biosciences Inc trades at $140.75 (market cap $14.36B). The key difference: Morgan Stanley is far larger — about 20.5× Neurocrine Biosciences Inc's market cap, and Morgan Stanley pays a 2.45% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 93 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MS | NBIX | |
|---|---|---|
Market Cap | $294.39B | $14.36B |
Volume | 5,836,423 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $228.42 | $185.50 |
52-Week Low | $151.86 | $123.10 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $660.04B | $14.37B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.
The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
